Skip to content

A clinical study to know the effects of a unani formulation in comparison to metformin in the management of type 2 diabetes mellitus.

Assessment of a polyherbal unani formulation in comparison to standard treatment for type 2 diabetes mellitus (ziabetus): A randomized control clinical trial. - Nil

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/12/098691
Enrollment
60
Registered
2025-12-09
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: PHUF ziabetus powder: Ingredients of PHUF ziabetus powder are Gurmar booti, Kalonji, Methi, Satte gilo and Maghz Tukhme Jamun in equal proportion. Recommended dose 5 gram orally twice a

Sponsors

Dr Md Zahid
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjective Parameters are Polyuria, Polydipsia, Tiredness/ Fatigue, weight loss and burning sensation in palms or soles. Objective Parameters are fasting plasma glucose range 126-150 mg/dl, post prandial plasma glucose range 200- 250 mg/dl and HbA1c range 6.5 to 8 percent.

Exclusion criteria

Exclusion criteria: Severe anemia ( Hemoglobin less than 8gram percent in females and hemoglobin less than 10 gram percent in males). Uncontrolled hypertension and CAD patients. Any chronic major illness like tuberculosis, CVA, thyroid disease. Pregnant and lactating women. Chronic hepatic and renal disorders patients. Patients having any type of malignancy, autoimmune and immunodeficiency disorders. Patients with congenital anomaly, mentally retarded and bed ridden.

Design outcomes

Primary

MeasureTime frame
Reduction in subjective parameters such as polyuria, polydipsia, tiredness and burning palms or soles. Body weight of the subjects should be constant or increased. Reduction in fasting plasma glucose and post prandial plasma glucose. Reduction in HBA1C level.Timepoint: 90 days

Secondary

MeasureTime frame
NilTimepoint: Nil

Countries

India

Contacts

Public ContactDr Md Najibur Rahman

Government Tibbi College and Hospital Kadam Kuan Patna

dr.razi.ahmed91@gmail.com7909045622

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026